 The FDA has approved KemPharm Incs NASDAQ: KMPH market application for Azstarys formerly referred to as KP415, a once-daily product for the treatment of attention deficit hyperactivity disorder ADHD in patients age six years and older. ADHD is a neurobehavioral disorder of childhood that makes it difficult for a person to pay attention and control impulsive behaviors. 